{
    "clinical_study": {
        "@rank": "3276", 
        "arm_group": [
            {
                "arm_group_label": "VCL-HB01, 0.25-mL dose", 
                "arm_group_type": "Experimental", 
                "description": "VCL-HB01, 0.25-mL dose by intramuscular injection once every 28 days for 3 doses"
            }, 
            {
                "arm_group_label": "PBS, 0.25-mL dose", 
                "arm_group_type": "Placebo Comparator", 
                "description": "PBS, 0.25-mL dose by intramuscular injection once every 28 days for 3 doses"
            }, 
            {
                "arm_group_label": "VCL-HB01, 0.5-mL dose", 
                "arm_group_type": "Experimental", 
                "description": "VCL-HB01, 0.5-mL dose by intramuscular injection once every 28 days for 3 doses"
            }, 
            {
                "arm_group_label": "PBS, 0.5-mL dose", 
                "arm_group_type": "Placebo Comparator", 
                "description": "PBS, 0.5-mL dose by intramuscular injection once every 28 days for 3 doses"
            }, 
            {
                "arm_group_label": "VCL-HB01, 1-mL dose", 
                "arm_group_type": "Experimental", 
                "description": "VCL-HB01, 1-mL dose by intramuscular injection once every 28 days for 3 doses"
            }, 
            {
                "arm_group_label": "VCL-HM01, 1-mL dose", 
                "arm_group_type": "Experimental", 
                "description": "VCL-HM01, 1-mL dose by intramuscular injection once every 28 days for 3 doses"
            }, 
            {
                "arm_group_label": "PBS, 1-mL dose", 
                "arm_group_type": "Placebo Comparator", 
                "description": "PBS, 1-mL dose by intramuscular injection once every 28 days for 3 doses"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the safety and effectiveness of two experimental\n      therapeutic vaccines against herpes simplex virus, type 2 (HSV-2)."
        }, 
        "brief_title": "Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Genital Herpes Simplex Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Herpes Genitalis", 
                "Herpes Simplex"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a dose escalation study to evaluate the safety, immunogenicity, and efficacy of 3\n      doses of HSV plasmid DNA (pDNA) vaccines formulated with Vaxfectin\u00ae in subjects with a\n      minimum of 1 year of reported history of genital herpes, and either 2 to 9 recurrences\n      within the year prior to screening, or 2 to 9 recurrences per year prior to starting\n      suppressive therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HSV-2 seropositive\n\n          -  A minimum of 1 year of reported history of genital herpes and either 2 to 9\n             recurrences within the year prior to screening or 2 to 9 recurrences per year prior\n             to starting suppressive therapy\n\n        Exclusion Criteria:\n\n          -  History of receiving an investigational HSV vaccine\n\n          -  Chronic illness for which a subject's immune system is suspected to be impaired or\n             altered, such as cancer, autoimmune conditions, or diabetes\n\n          -  Pregnant or breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "156", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02030301", 
            "org_study_id": "HSV2-101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "VCL-HB01, 0.25-mL dose", 
                    "VCL-HB01, 0.5-mL dose", 
                    "VCL-HB01, 1-mL dose"
                ], 
                "description": "Plasmid DNA vaccine encoding two HSV-2 proteins; formulated with Vaxfectin\u00ae", 
                "intervention_name": "VCL-HB01", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "VCL-HM01, 1-mL dose", 
                "description": "Plasmid DNA vaccine encoding one HSV-2 protein; formulated with Vaxfectin\u00ae", 
                "intervention_name": "VCL-HM01", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "PBS, 0.25-mL dose", 
                    "PBS, 0.5-mL dose", 
                    "PBS, 1-mL dose"
                ], 
                "description": "Phosphate-buffered saline", 
                "intervention_name": "PBS", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Herpes Simplex Virus, Type 2", 
            "Herpes", 
            "HSV-2"
        ], 
        "lastchanged_date": "April 30, 2014", 
        "location": [
            {
                "contact": {
                    "email": "lesliejo@uab.edu", 
                    "last_name": "Leslie Christian", 
                    "phone": "205-934-6774"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "Alabama Vaccine Research Clinic"
                }, 
                "investigator": {
                    "last_name": "Nicholas Van Wagoner, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kimberlygardner@phase1solutions.com", 
                    "last_name": "Kimberly Gardner", 
                    "phone": "305-624-9191", 
                    "phone_ext": "8078"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami Gardens", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33169"
                    }, 
                    "name": "Phase 1 Solutions"
                }, 
                "investigator": {
                    "last_name": "Lawrence Galitz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "elargent@iu.edu", 
                    "last_name": "Elisha Largent, RN", 
                    "phone": "317-278-1614"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University Infectious Diseases Research"
                }, 
                "investigator": {
                    "last_name": "Kenneth Fife, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rene@westoverheights.com", 
                    "last_name": "Rene Bernert", 
                    "phone": "503-226-6678"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "Westover Heights Clinic"
                }, 
                "investigator": {
                    "last_name": "Terri Warren, ANP, RN", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "info@ccstexas.com", 
                    "last_name": "Jesse Villanueva", 
                    "phone": "713-528-8818", 
                    "phone_ext": "1201"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77004"
                    }, 
                    "name": "Center for Clinical Studies"
                }, 
                "investigator": {
                    "last_name": "Steve K. Tyring, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bryce.moulton@hsc.utah.edu", 
                    "last_name": "Bryce Moulton", 
                    "phone": "801-587-3831"
                }, 
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84132"
                    }, 
                    "name": "University of Utah - Division of Infectious Diseases"
                }, 
                "investigator": {
                    "last_name": "John Kriesel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kahauge@uw.edu", 
                    "last_name": "Kirsten Hauge", 
                    "phone": "206-520-4340"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "University of Washington Medical Center"
                }, 
                "investigator": {
                    "last_name": "Anna Wald, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "7", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults", 
        "other_outcome": [
            {
                "measure": "Genital shedding rate change from baseline over time", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 150, Day 330"
            }, 
            {
                "measure": "Subclinical genital shedding rate change from baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 150"
            }
        ], 
        "overall_official": {
            "affiliation": "Vical", 
            "last_name": "Mammen P. Mammen, Jr., MD,FACP,FIDSA", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 420"
            }, 
            {
                "measure": "Viral shedding rate change from baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 150"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02030301"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Genital lesion rate change from baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 150"
            }, 
            {
                "measure": "HSV DNA copy numbers change from baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 150"
            }, 
            {
                "measure": "Genital recurrence rate compared with placebo", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 330"
            }, 
            {
                "measure": "T-cell and/or antibody responses change from baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Days 7, 35, 63, 150, 330"
            }
        ], 
        "source": "Vical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}